A 41-year-old woman is brought to the emergency department by her husband due to progressi… — USMLE Step 2 CK

A $41$ -year-old woman is brought to the emergency department by her husband due to progressive weakness, easy bruising, and persistent bleeding from her gums for the past $48$ hours. Her temperature is $37.6^\circ\text{C}$ ( $99.7^\circ\text{F}$ ), blood pressure is $110/70\text{ mmHg}$ , and heart rate is $108\text{/min}$ . Physical examination reveals widespread petechiae and purpura over her extremities.

Laboratory studies show:
- Hemoglobin: $7.8\text{ g/dL}$
- Leukocyte count: $4,500\text{/mm}^3$ (with $60\%$ atypical promyelocytes)
- Platelet count: $18,000\text{/mm}^3$
- Prothrombin time: $22\text{ sec}$ (prolonged)
- Activated partial thromboplastin time: $54\text{ sec}$ (prolonged)
- Fibrinogen: $60\text{ mg/dL}$ (decreased)
- D-dimer: $>10,000\text{ ng/mL}$ (markedly elevated)

A peripheral blood smear demonstrates large, abnormal myeloid cells with prominent primary granules and multiple rod-like cytoplasmic inclusions.

Arrange the following steps in the most appropriate chronological order for the diagnosis and management of this patient.

1Administer all-trans retinoic acid (ATRA).
2Obtain a bone marrow aspirate for PML-RARA molecular testing.
3Initiate definitive induction therapy by adding arsenic trioxide.
4Perform a follow-up bone marrow analysis to verify molecular remission.

Answer

The correct chronological order is to first administer ATRA based on clinical suspicion, then obtain a bone marrow aspirate for molecular confirmation, followed by the addition of definitive induction agents like arsenic trioxide, and finally, after consolidation, performing follow-up testing to confirm molecular remission.

The correct sequence for managing suspected acute promyelocytic leukemia (APL) prioritizes immediate stabilization of the life-threatening coagulopathy, followed by definitive diagnosis and long-term management. First, ATRA must be started immediately upon morphological suspicion (faggot cells) and clinical presentation (DIC) to induce differentiation and halt the coagulopathy. Delaying ATRA for bone marrow confirmation is a classic error that increases mortality. Second, once ATRA is started and the patient is stabilized (often concurrently with blood product transfusion), a bone marrow aspirate is obtained to molecularly confirm the t(15;17) PML-RARA translocation. Third, following confirmation, definitive induction therapy is completed by adding arsenic trioxide (ATO) to the ATRA regimen. Finally, after induction and consolidation therapies are completed, follow-up bone marrow testing is performed to verify complete molecular remission.

Step-by-Step Solution

Administer all-trans retinoic acid (ATRA)

Drives differentiation of leukemic promyelocytes and halts the severe coagulopathy.

APL is a medical emergency due to the high risk of fatal hemorrhage from disseminated intravascular coagulation (DIC). ATRA must be started at the first clinical or morphological suspicion, even before genetic confirmation is obtained.

Obtain a bone marrow aspirate for PML-RARA molecular testing

Definitively confirms the diagnosis of APL.

While ATRA is started empirically, molecular confirmation of the t(15;17) translocation is required to guide long-term therapy. The bone marrow biopsy should be obtained promptly, but it must not delay the initiation of ATRA.

Initiate definitive induction therapy by adding arsenic trioxide

Completes the induction regimen to achieve hematologic remission.

Once the genetic diagnosis is confirmed, comprehensive induction therapy (typically combining ATRA with arsenic trioxide) is instituted to induce a complete remission.

Perform a follow-up bone marrow analysis to verify molecular remission

Assesses the eradication of the leukemic clone.

After the completion of induction and consolidation therapy, patients require follow-up molecular testing of the bone marrow to ensure the PML-RARA transcript is undetectable.

Key Concept

In patients with suspected acute promyelocytic leukemia (APL), all-trans retinoic acid (ATRA) must be administered immediately upon morphological suspicion to prevent fatal coagulopathy, prior to obtaining genetic confirmation via bone marrow biopsy.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic